ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03 Amendment of Articles of Incorporation
On January 10, 2018 Entest Biomedical, Inc. ( the “Company”) filed a Certificate of Amendment with the Nevada Secretary of State authorizing a change to the Company’s Articles of Incorporation.
The change is as follows:
Effective February 12, 2018 the name of the Company shall be Entest Group, Inc.
Item 9.01 Exhibits.
| Exhibit No. | Description of Exhibit |
| 3(i) | TEXT OF CERTIFICATE OF AMENDMENT. |
ENTEST BIOMEDICAL, INC. ExhibitEX-3.I 2 ex3i.htm EXHIBIT 3(I) Exhibit 3(i) Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390-After Issuance of Stock) Name of Corporation: Entest Biomedical,…To view the full exhibit click here
About ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB)
Entest BioMedical, Inc. is engaged in the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is engaged in the development and commercialization of ImenVax, a therapeutic cancer vaccine for use in canines, and the development and commercialization of certain intellectual property for non-human veterinary therapeutic use. Its products include ImenVax I, ImenVax II, ImenVax III and ENT-576. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II is in early-stage of development. ImenVax III is intended to function by harnessing the ability of placental extracts to combat canine cancers. It is developing ENT-576 for the treatment of chronic obstructive pulmonary disease (COPD).